Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
Akbar S, Raza A, Mohsin R, Kanbour A, Qadri S, Parray A, Zar Gul AR, Philip A, Vijayakumar S, Merhi M, Hydrose S, Inchakalody VP, Al-Abdulla R, Abualainin W, Sirriya SA, Al-Bozom I, Uddin S, Khan OM, Mohamed Ibrahim MI, Al Homsi U, Dermime S.
Akbar S, et al. Among authors: parray a.
Front Immunol. 2023 Jan 18;13:1097117. doi: 10.3389/fimmu.2022.1097117. eCollection 2022.
Front Immunol. 2023.
PMID: 36741391
Free PMC article.